The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bavarian Nordic; Bayer; Bellicum Pharmaceuticals; Blue Earth Diagnostics; Celgene; Constellation Pharmaceuticals; Dendreon; EMD Serono; Endocyte; Johnson & Johnson; Myovant Sciences; Pfizer; Progenics; Sanofi; Teva
Research Funding - AstraZeneca; Bayer; Bristol-Myers Squibb; Constellation Pharmaceuticals; Dendreon; Endocyte; Innocrin Pharma; InVitae; Johnson & Johnson; Merck; Progenics; Roche; Sanofi; Sotio
Expert Testimony - Sanofi
Travel, Accommodations, Expenses - Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; Bavarian Nordic; Bayer; Bellicum Pharmaceuticals; Blue Earth Diagnostics; Bristol-Myers Squibb; Bristol-Myers Squibb; Celgene; Constellation Pharmaceuticals; Dendreon; EMD Serono; EMD Serono; Endocyte; Endocyte; Innocrin Pharma; Innocrin Pharma; InVitae; InVitae; Johnson & Johnson; Johnson & Johnson; Merck; Merck; Myovant Sciences; Myovant Sciences; Pfizer; Pfizer; Progenics; Progenics; Roche; Roche; Sanofi; Sanofi; Sotio; Sotio; Teva; Teva
ProSTAR: A phase Ib/II study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC).
 
Mary-Ellen Taplin
Honoraria - Astellas Pharma; Bayer; Clovis Oncology; Incyte; Janssen-Ortho; Pfizer; Research to Practice; UpToDate
Consulting or Advisory Role - AstraZeneca; Bayer; Best Doctors, Inc; Clovis Oncology; Guidepoint Global; Incyte; Janssen-Ortho; Myovant Sciences; Pfizer; Research to Practice; UpToDate
Research Funding - Bayer (Inst); Janssen-Ortho (Inst); Medivation (Inst); Pfizer (Inst); Tokai Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Clovis Oncology; Incyte; Janssen Oncology; Medivation; Pfizer; Tokai Pharmaceuticals
 
Arif Hussain
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Novartis
Research Funding - Agensys; Bayer; Cerulean Pharma; Clovis Oncology; Merck; Sotio
 
Satish Shah
Employment - Flatiron Health (I); Flatiron Health (I); Flatiron Health (I); Flatiron Health (I); Flatiron Health (I); Flatiron Health (I); Flatiron Health (I); OneOncology (I)
Stock and Other Ownership Interests - Flatiron Health (I)
 
Neal D. Shore
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Dendreon; Ferring; Genentech/Roche; Janssen Scientific Affairs; Medivation/Astellas; Myovant Sciences; Pfizer; Tolmar
Speakers' Bureau - Bayer; Dendreon; Janssen
 
Manish Agrawal
No Relationships to Disclose
 
William Clark
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Constellation Pharmaceuticals; GTx; Janssen; Pfizer
 
William Jeffery Edenfield
Speakers' Bureau - Astellas Medivation; Novartis
 
Luke T. Nordquist
No Relationships to Disclose
 
Oliver A Sartor
No Relationships to Disclose
 
James E. Butrynski
No Relationships to Disclose
 
Gurkamal S. Chatta
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - Bristol-Myers Squibb
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb
 
Mark T. Fleming
Employment - Virginia Oncology Associates
Speakers' Bureau - Genentech; Janssen Oncology
Travel, Accommodations, Expenses - Genentech; Medivation/Astellas
 
William K. Oh
Leadership - checkpoint Sciences
Stock and Other Ownership Interests - Bellicum Pharmaceuticals
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; checkpoint Sciences; Churchill Pharmaceuticals; Dendreon; Inovio Pharmaceuticals; Janssen; Sanofi; Sema4; TYME
Research Funding - Sotio (Inst)
 
Bill Bradley
Employment - Constellation Pharmaceuticals
Stock and Other Ownership Interests - Constellation Pharmaceuticals
Honoraria - Cell Signaling Technology
Patents, Royalties, Other Intellectual Property - Constellation Pharmaceuticals
 
Jessica Piel
Employment - Constellation Pharmaceuticals
Stock and Other Ownership Interests - Constellation Pharmaceuticals; Novartis
Research Funding - Trovagene (I)
Patents, Royalties, Other Intellectual Property - Trovagene (I)
 
David Nash
Employment - Constellation Pharmaceuticals
Stock and Other Ownership Interests - Constellation Pharmaceuticals; Radius Health
 
Gozde Colak
Employment - Constellation Pharmaceuticals
Stock and Other Ownership Interests - Constellation Pharmaceuticals; Shire
 
Jian Li
Employment - Constellation Pharmaceuticals
Stock and Other Ownership Interests - Cerulean Pharma; Constellation Pharmaceuticals; Syndax
 
Claudia Lebedinsky
Employment - Constellation Pharmaceuticals
Stock and Other Ownership Interests - Constellation Pharmaceuticals
 
Emmanuel S. Antonarakis
Honoraria - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi